VANCOUVER, British Columbia, Jan. 5, 2018 /PRNewswire/ --MYM Nutraceuticals Inc. (CSE: MYM) (CSE: MYM.CN) (OTC: MYMMF) ("MYM") is excited to announce that Australia will expunge the export ban on cannabis products in February 2018 and allow the worldwide exportation of cannabis-based treatments such as oils, patches, sprays, lozenges and tablets. The Australian Federal Government has big ambitions for Australia to become the largest producer of medicinal cannabis products in the world.
Australia's Health Minister Greg Hunt stated, "We would like to be, potentially, the world's number one medicinal cannabis supplier. One of the conditions of any license for export is that medicinal cannabis be made available to Australian patients first. The sector is fully supportive of that. Australian patients come first. There are now no real government barriers at all to accessing medicinal cannabis."
This is fantastic news for MYM since it has an Australian joint venture company, Solaris Nutraceuticals, that is currently in the assessment phase of the licensing process to build a 1.2 million square-foot greenhouse facility set to be the largest cannabis production facility in Australia. MYM expects that exportation of cannabis products from Australia will be big business and could even outstrip domestic sales.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
About Solaris Nutraceuticals Inc.
Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. It has submitted an application and plans with Australia's Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia. Solaris's corporate mission is to deliver environmentally friendly, sun-grown medicinal-grade cannabis and to develop medicines and treatments for pain management and other medical conditions. The company's focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit www.solarisnutraceuticals.com.
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
Keep up to date with MYM on our social media channels:
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
SOURCE MYM Nutraceuticals Inc.